Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.


Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

First demonstration of the potential of scMRD assay to provide actionable insights into measurable residual disease (MRD) in acute myeloid leukemia (AML)

24 presentations featuring data generated by top pharma and academic institutions utilizing Tapestri for a broad range of indications in hematology 


SOUTH SAN FRANCISCO, Calif., Dec. 7, 2023Mission Bio, a leader in single-cell multiomic solutions for precision medicine, announced today new data generated by clinical researchers from leading biopharma companies and top academic institutions will be showcased at the 65th ASH Annual Meeting and Exposition. This announcement follows on the heels of the successful launch of the company’s scMRD Assay, to which the latest data on 48 samples from the Clínica Universidad de Navarra will be featured in a poster presentation at the conference. The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine. 


At the American Society of Hematology (ASH) conference, being held in San Diego on December 9-12, world-leading scientists will present results demonstrating Tapestri’s capabilities to uncover critical insights into clonal dynamics, therapeutic response mechanisms, and clones driving disease persistence and relapse, reflecting the platform’s unique capabilities and position in the market. 


Included among the presentations is the first data demonstrating the potential actionability of Mission Bio’s Tapestri® Single-Cell MRD (scMRD) AML Multiomics Assay, which will be presented from the lab of Felipe Prosper, MD, PhD, Co-director of the Hematology and Cell Therapy Unit at the Clínica Universidad de Navarra, highlighting its feasibility for assessing MRD in AML patients. 


“Understanding the genetic heterogeneity at the single-cell level is crucial to the discovery and development of safer and more effective treatments for blood cancers,” said Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio. “We’re excited to see so many of our customers leverage Tapestri, validating the scientific merit of our technology, demonstrating its practical application in a clinical setting, and substantiating the impact of single-cell data to potentially transform care by guiding more personalized treatments in AML, multiple myeloma (MM), and other blood cancers.  


Among the ASH presentations, researchers from Dr. Prosper’s lab will present results demonstrating the concordance between Mission Bio’s scMRD assay and the gold-standard techniques for MRD, such as PCR and multiparameter flow cytometry (MFC), in AML patient samples. The data suggest the scMRD Multiomics Assay’s potential role in advancing targeted therapeutic approaches and its influence on treatment paradigms in the future. 


In the presentation, “Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones,” the researchers showed that Mission Bio’s scMRD AML Multiomics Assay: 


  • Identified rare leukemic clones that were missed by conventional assays.
  • Distinguished clonality of clinically actionable mutations, compared to MFC and PCR data, which only designated MRD status.
  • Detected MRD-positive patients, which were deemed negative by MFC and PCR,
  • Differentiated between clonal hematopoiesis (CH) clones and leukemic clones.


“Patients suffering from relapsed AML have poor overall survival, necessitating more effective methods for MRD monitoring and detection to better understand the genomic landscape of clonal evolution,” said Dr. Prosper. “This impressive data is a significant step towards demonstrating the feasibility of Mission Bio’s assay to detect and monitor MRD in AML patients, to ultimately enable more effective therapeutic strategies, including combination and targeted therapies, based on insights from single-cell DNA and protein multiomics for improved patient outcomes in the future.”


These results follow Mission Bio’s successful commercial launch of the scMRD AML Multiomics Assay, designed to offer deep genotypic and immunophenotypic insights into MRD signatures within individual cells.


“Multiple Myeloma therapy, similarly to other blood cancers like AML, remains a challenge and huge unmet medical need because of the poor prognosis and high relapse rate. Tapestri’s ability to combine SNVs, CNVs, and surface protein expression at a single-cell level will be crucial to myeloma surveillance and understanding clonal evolution, and our ability to fully realize precision medicine,” said Cedric Dos Santos, PhD, Director AML/MDS/MM, Translational Medicine, at Genentech.


Data from other blood cancer studies will be presented by leading researchers in over 24 presentations leveraging Mission Bio’s Tapestri Platform, showcasing its broad application in hematology. These studies from institutions including Genentech, Merck, MD Anderson Cancer Center, Broad Institute of MIT and Harvard, and St. Jude Children’s Research Hospital embody Mission Bio’s commitment to advancing hematological research. For a complete list of ASH presentations using Tapestri, please visit our website.


About Mission Bio 

Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit



Media Contact

Consort Partners for Mission Bio

Mission Bio Announces Launch of First Single-Cell Multiple Myeloma Multiomics Solution Aimed to Transform Translational Research and Therapy Development
Mission Bio’s Tapestri Platform Unveils Insights into Targeted Therapy and Residual Disease Assessment for Multiple Myeloma
Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets